HGH vs IGF-1: Growth Hormone and Its Mediator Compared

Growth hormone and IGF-1 are routinely mentioned together, and the two are often conflated. They are, in fact, two physically distinct molecules connected by a single regulatory axis. Human growth hormone (HGH / somatropin / GH) is the upstream pituitary hormone. Insulin-like growth factor 1 (IGF-1) — historically named somatomedin C — is a separate, smaller peptide that the liver produces in response to growth hormone and which carries out many of growth hormone's downstream effects.

Research-use-only: This page describes endogenous human biochemistry to contrast two molecules. It is not medical advice, a treatment recommendation, or a dosing guide, and it makes no efficacy or outcome claims. RetaLABS supplies HGH (somatropin) as a research compound; it does not sell IGF-1 or any IGF-1 analogue, and nothing here should be read as offering one.

The distinction matters because the two molecules differ in almost every structural respect — size, amino-acid count, receptor, receptor class, signalling cascade and circulating half-life. This article sets those properties side by side. For the broader axis overview and the role each plays in growth-hormone biology, see the HGH research guide; this page focuses specifically on the molecular-level comparison rather than re-describing the axis.

The clearest way to separate the two molecules is to place their confirmed structural and pharmacological properties next to each other. Every value below is drawn from primary records — UniProt and the FDA INCRELEX label for the physical constants, and the receptor/signalling reviews cited at the end of this page.

The two rows that most define the difference are receptor class and half-life. Growth hormone's receptor is a cytokine-class receptor with no intrinsic enzymatic activity, whereas IGF-1's receptor is a receptor tyrosine kinase that autophosphorylates on ligand binding. And where growth hormone clears within minutes, the bulk of circulating IGF-1 persists for hours because it travels bound to carrier proteins — the subject of a later section.

The functional link between the two molecules is the somatomedin hypothesis, formalised in its modern form by Le Roith and colleagues (Endocrine Reviews, 2001). In this framework, growth hormone is the signal and IGF-1 is much of the message: growth hormone released from the pituitary acts on the liver, and the liver responds by synthesising and secreting IGF-1, which then mediates a large share of growth hormone's anabolic and growth-promoting effects in peripheral tissues.

This is why the two are so easily confused — measuring circulating IGF-1 is a common way to gauge growth-hormone-axis activity, because hepatic IGF-1 output tracks growth-hormone stimulation. But "tracks" is not "is identical to." IGF-1 is a separate gene product (gene IGF1, UniProt accession P05019) with its own receptor and its own kinetics. Growth hormone is the upstream regulator; IGF-1 is the downstream effector. The two should be held as distinct entities even when they are studied as one pathway.

Not every action of growth hormone runs through IGF-1. The literature distinguishes direct growth-hormone effects, mediated by the GH receptor on target tissues, from indirect effects mediated by IGF-1 after the liver has been stimulated.

• Direct GH effects include lipolysis in adipose tissue and antagonism of insulin action — effects that do not depend on IGF-1 and that Clemmons (J Clin Invest, 2004) attributes to growth hormone acting on its own receptor.
• IGF-1-mediated effects include much of the growth and anabolic signalling, carried out once growth hormone has driven hepatic IGF-1 production, consistent with the somatomedin framework of Le Roith and colleagues.

One of the sharpest contrasts is on insulin sensitivity, where the two molecules pull in opposite directions. As Clemmons sets out, growth hormone tends to antagonise insulin action and can induce insulin resistance, while IGF-1 tends to enhance insulin sensitivity. That two molecules sitting on the same axis can have opposing metabolic effects is one of the strongest reasons not to treat "GH" and "IGF-1" as interchangeable shorthand for the same thing.

The single biggest kinetic difference between the two molecules comes from the IGF binding proteins (IGFBPs). As reviewed by Allard and Duan (Frontiers in Endocrinology, 2018), vertebrates have six principal high-affinity IGFBPs (IGFBP-1 through IGFBP-6), and these bind the great majority of circulating IGF, modulating its transport, bioavailability and access to the IGF-1 receptor.

The practical consequence is a dramatic spread in half-life depending on what the IGF-1 is bound to:

• Free, unbound IGF-1 has a half-life of less than 10 minutes.
• Bound in a binary IGF·IGFBP complex, half-life extends to roughly 30–90 minutes.
• Bound in the ternary complex (IGF-1 plus IGFBP-3 or IGFBP-5 plus the acid-labile subunit, ALS), the review states the half-life is prolonged to about 16 hours or more.

This is why a small peptide that is intrinsically short-lived nonetheless circulates as a long-lived pool: most of it is sequestered in the ternary complex. Growth hormone, by contrast, has no comparable carrier system and is eliminated within minutes (an IV elimination half-life of roughly 14–19 minutes). When comparing "half-life," then, it is essential to specify which IGF-1 pool is meant — the free figure and the bound figure differ by orders of magnitude.

Outside of native human IGF-1, the research literature also describes engineered analogues. The most frequently mentioned is IGF-1 LR3 (Long R3 IGF-1). It is included here only as context for why a laboratory analogue behaves differently from the endogenous peptide — RetaLABS does not sell IGF-1 LR3, and it is not part of the catalogue.

Qualitatively, IGF-1 LR3 differs from native IGF-1 in a few well-described ways: it is a longer molecule of 83 amino acids (versus 70 for native IGF-1); it carries an arginine substitution at position 3 in place of the native residue; and it has a 13-amino-acid N-terminal extension (the "long" in its name). These modifications give it reduced affinity for the IGF binding proteins, and because IGFBP binding is what governs the circulating half-life of native IGF-1 (see the previous section), the analogue's reduced binding is associated with a longer half-life than native IGF-1. The exact N-terminal extension sequence and precise half-life values are not asserted here, as they are not confirmed against primary structural literature. The takeaway is conceptual: an engineered analogue that evades the IGFBP system circulates differently from the natural hormone.

In short: growth hormone is the larger upstream pituitary hormone (191 amino acids, ~22.1 kDa) that signals through a cytokine-class receptor; IGF-1 is the smaller downstream mediator (70 amino acids, 7,649 Da) that the liver makes in response, signals through a receptor tyrosine kinase, and circulates bound to a family of six binding proteins that stretch its effective half-life from minutes to many hours. They share an axis but are not the same molecule — and on insulin sensitivity they act in opposite directions. RetaLABS supplies HGH (somatropin) as a research compound and does not offer IGF-1 in any form.

Sources:

• Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74. PMID 11159816.
• Khan MZ, Zugaza JL, Torres Aleman I. The signaling landscape of insulin-like growth factor 1. J Biol Chem. 2024. PMID 39638246.
• Allard JB, Duan C. IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? Front Endocrinol. 2018;9:117. PMID 29686648.
• Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest. 2004;113(1):25–27. PMID 14702105.
• UniProt P05019 — Insulin-like growth factor I (Homo sapiens).

Continue across the HGH research cluster: the HGH research guide for the full somatotropic-axis overview, the HGH molecular profile for somatropin's formula, mass and identifiers, and the HGH vs CJC-1295/Ipamorelin comparison for direct hormone versus secretagogue approaches. For applied physiology, see the HGH body composition research, the HGH and sleep research, and the HGH pharmacokinetics reference. Research-grade vials: HGH 100IU kit, HGH 240IU kit, and HGH 400IU kit.